FORTREA HOLDINGS INC
FTRENASDAQTrading Snapshot
- Day Range
- $24.30 – $26.16
- 52-Week Range
- $8.55 – $24.84
- Volume (shares)
- 3,587,141
- Avg Volume (shares)
- —
- Shares Outstanding
- 95.1M
- Next Earnings
- 2026-10-29
Fundamentals Snapshot
- Annual Revenue
- $2.72B
- Last Q Revenue
- $678M
- P/E Ratio
- -26.3
- P/S Ratio
- 0.9x
- EPS (TTM)
- $-0.90
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1.3%
FORTREA HOLDINGS INC
FTRE
StockOtter · stockotter.spaceAbout FORTREA HOLDINGS INC
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Fortrea to Participate in Jefferies Global Healthcare Conference
DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations
Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Aust
Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials
Highlights Fortrea completes acquisition of the Early Phase Services division from Worldwide Clinical Trials Adds a 60,000-square-foot GLP-compliant bioanalytical laboratory in Austin, Texas; a 200-bed GCP-compliant clin
3 Top Small-Cap Stocks With Market-Beating Momentum
Small-cap stocks have surrendered their lead over large caps in 2026 amid rising Treasury yields, but historical data shows small caps can rebound strongly when yields decline. Bank of America strategists see potential f
MindWalk (NASDAQ:HYFT) & Fortrea (NASDAQ:FTRE) Head to Head Contrast
Fortrea (NASDAQ: FTRE - Get Free Report) and MindWalk (NASDAQ: HYFT - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of t